---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-276738"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2026-06-22T12:14:24+00:00"
generated_at: "2026-06-22T12:15:18.754748+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Taysha completes REVEAL pivotal trial dosing; longer-term data shows durable functional gains in Rett syndrome

## Summary
- Completed dosing of 17 patients in REVEAL pivotal trial; topline 6-month interim data and FDA feedback expected 1H 2027.
- 100% of 12 REVEAL Part A patients gained/regained ≥1 developmental milestone by 12 months post-TSHA-102.
- No treatment-related SAEs or DLTs across 29 patients dosed as of June 2026 cutoff.
- 310 total functional gains observed ≥12 months post-treatment (~26 per patient) across core disease domains.
- ASPIRE trial enrollment exceeded; expects to dose 4th patient in July 2026; safety data to support BLA.

## SEC filing metadata
- accession: 0001193125-26-276738
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2026-06-22T12:14:24+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/0001193125-26-276738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-276738
- JSON: https://secwatch.observer/filing/0001193125-26-276738.json
- Plain text: https://secwatch.observer/filing/0001193125-26-276738.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.